Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Navidea Biopharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NAVB
Over the counter
8731
https://www.navidea.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
- Jan 27th, 2024 12:05 am
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
- Dec 1st, 2023 1:30 pm
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock
- Oct 6th, 2023 1:01 am
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
- Aug 10th, 2023 1:29 pm
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
- Jul 31st, 2023 1:32 pm
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
- Jul 29th, 2023 12:23 am
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
- Jul 27th, 2023 9:20 pm
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
- Jul 13th, 2023 9:09 pm
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
- Jun 30th, 2023 1:16 pm
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
- Jun 16th, 2023 8:54 pm
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment
- Jun 16th, 2023 5:52 pm
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
- Jun 7th, 2023 8:00 pm
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
- Jun 2nd, 2023 9:54 pm
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down
- Jun 1st, 2023 9:53 pm
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market
- May 22nd, 2023 10:30 pm
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer
- May 11th, 2023 9:35 pm
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications
- May 8th, 2023 8:12 pm
Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit
- Apr 27th, 2023 9:14 pm
Scroll